Alector Shares Surge Following Licensing Deal with Genentech

Key Facts

1Alector shares surged following the announcement of a licensing agreement with Genentech.

Alector shares surged following the announcement of a licensing agreement with Genentech. Seeking Alpha reported that the price action was triggered by investor optimism regarding the strategic partnership, which grants Genentech global rights to develop and commercialize the AL050 program for Parkinson's and other neurodegenerative diseases.

ALEC closed at $1.81 on October 2, 2026, prior to the licensing news that validated the biotech firm's clinical pipeline. The stock reached a high of $1.97 and a low of $1.8 during that session.